UPDATE: Feltl and Company Reiterates NxStage Medical at Hold; Reduces 2012 Revenue Estimates
Feltl and Company reiterated its Hold rating and $15 price target on NxStage Medical (NASDAQ: NXTM) as it tweaked the revenue forecast for 2012 to reflect shift in shipment from the third quarter to the fourth.
Feltl and Company noted, "We are modestly adjusting our Home revenue model assumptions as it has become clearer the Home business is running below the company's $1.2 million to $1.6 million sequential growth rate target, and at this point we have no reason to believe a near term acceleration is likely. We now model $0.9 million and $1.0 million sequential growth for 3Q12 and 4Q12, equating to $64.3 million of Home revenue during the second half of 2012, down 1.3% from our previous estimates."
NxStage Medical closed at $13.25 on Thursday.
Latest Ratings for NXTM
|Feb 2015||Canaccord Genuity||Maintains||Buy|
|Sep 2014||Canaccord Genuity||Maintains||Buy|
|Mar 2014||Wells Fargo||Downgrades||Market Perform||Underperform|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.